AMYLYX PHARMACEUTICALS INC (AMLX)
Sector: Health Care
2026 Annual Meeting Analysis
AMYLYX PHARMACEUTICALS INC · Meeting: June 4, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Dr. Milne has served since 2015 and the 3-year TSR trigger does not apply because AMLX's 3-year return (-44.4%) is only 3.9 percentage points below the peer group median (-48.3%), well within the 20-point threshold required to trigger a vote against; he brings deep pharmaceutical industry experience and no overboarding, independence, attendance, or other disqualifying flags are present.
Mr. Fonteyne has served since March 2021 and the 3-year TSR trigger does not apply given AMLX outperforms its peer group median by 3.9 percentage points over three years; he has relevant life sciences executive experience, all board and committee meetings attendance requirements are met, and no overboarding, independence, or other disqualifying flags are present.
Both Class II director nominees pass all policy screens. The primary TSR concern — AMLX's negative 3-year absolute return of -44.4% — is evaluated against the company's disclosed peer group (14 small-cap biotech peers), where the peer median 3-year return is -48.3%, meaning AMLX actually outperformed its peers by 3.9 percentage points, well below the 20-point underperformance threshold needed to trigger a vote against. All directors attended at least 75% of meetings, no overboarding issues exist, and both nominees have strong relevant qualifications.
Say on Pay
✓ FORCEO
Justin Klee
Total Comp
$2,719,807
Prior Support
58%%
The prior year Say on Pay vote received only approximately 58% support — below the 70% threshold that triggers a heightened review — and the policy requires a vote against if the company made no visible changes. However, Amylyx did make meaningful structural changes in response: it froze all executive base salaries at 2024 levels, introduced performance-based stock awards (tied to specific avexitide clinical and regulatory milestones) for the first time, enhanced compensation disclosure, and added a formal peer group to the proxy. The CEO's total compensation of $2,719,807 is reasonable for a biotech co-CEO at a ~$1.9 billion market-cap company, pay mix includes meaningful variable components (bonus paid at 106.5% of target based on verified corporate goal achievement, plus equity with multi-year vesting and performance conditions), and the company maintains a proper clawback policy; taken together, the company has made sufficient and visible good-faith improvements in response to last year's shareholder feedback to warrant a FOR vote this year.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
6 yrs
Audit Fees
$862,500
Non-Audit Fees
$0
Deloitte has audited Amylyx since 2020 (approximately 6 years), well below the 25-year tenure threshold that would raise independence concerns; in fiscal year 2025, the company paid $862,500 in audit fees and zero in non-audit fees, meaning the non-audit fee ratio is 0% — far below the 50% threshold that would trigger a vote against; Deloitte is a Big 4 firm appropriate for a company of Amylyx's size and complexity.
Overall Assessment
The 2026 Amylyx annual meeting ballot contains three standard proposals — director elections, auditor ratification, and Say on Pay — all of which receive a FOR vote determination under the policy. The most important judgment call is Say on Pay, where last year's low 58% shareholder support triggered enhanced scrutiny, but the company responded with meaningful compensation reforms (frozen salaries, new performance-based equity awards, improved disclosure, and peer group transparency) sufficient to support approval this year.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing